@article {144, title = {A cross-population atlas of genetic associations for 220 human phenotypes.}, journal = {Nat Genet}, volume = {53}, year = {2021}, month = {2021 10}, pages = {1415-1424}, abstract = {

Current genome-wide association studies do not yet capture sufficient diversity in populations and scope of phenotypes. To expand an atlas of genetic associations in non-European populations, we conducted 220 deep-phenotype genome-wide association studies (diseases, biomarkers and medication usage) in BioBank Japan (n = 179,000), by incorporating past medical history and text-mining of electronic medical records. Meta-analyses with the UK Biobank and FinnGen (n = 628,000) identified ~5,000 new loci, which improved the resolution of the genomic map of human traits. This atlas elucidated the landscape of pleiotropy as represented by the major histocompatibility complex locus, where we conducted HLA fine-mapping. Finally, we performed statistical decomposition of matrices of phenome-wide summary statistics, and identified latent genetic components, which pinpointed responsible variants and biological mechanisms underlying current disease classifications across populations. The decomposed components enabled genetically informed subtyping of similar diseases (for example, allergic diseases). Our study suggests a potential avenue for hypothesis-free re-investigation of human diseases through genetics.

}, keywords = {ABO Blood-Group System, Biological Specimen Banks, Genetic Association Studies, Genetic Loci, Genetic Pleiotropy, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Major Histocompatibility Complex, Meta-Analysis as Topic, Mutation, Phenotype}, issn = {1546-1718}, doi = {10.1038/s41588-021-00931-x}, author = {Sakaue, Saori and Kanai, Masahiro and Tanigawa, Yosuke and Karjalainen, Juha and Kurki, Mitja and Koshiba, Seizo and Narita, Akira and Konuma, Takahiro and Yamamoto, Kenichi and Akiyama, Masato and Ishigaki, Kazuyoshi and Suzuki, Akari and Suzuki, Ken and Obara, Wataru and Yamaji, Ken and Takahashi, Kazuhisa and Asai, Satoshi and Takahashi, Yasuo and Suzuki, Takao and Shinozaki, Nobuaki and Yamaguchi, Hiroki and Minami, Shiro and Murayama, Shigeo and Yoshimori, Kozo and Nagayama, Satoshi and Obata, Daisuke and Higashiyama, Masahiko and Masumoto, Akihide and Koretsune, Yukihiro and Ito, Kaoru and Terao, Chikashi and Yamauchi, Toshimasa and Komuro, Issei and Kadowaki, Takashi and Tamiya, Gen and Yamamoto, Masayuki and Nakamura, Yusuke and Kubo, Michiaki and Murakami, Yoshinori and Yamamoto, Kazuhiko and Kamatani, Yoichiro and Palotie, Aarno and Rivas, Manuel A and Daly, Mark J and Matsuda, Koichi and Okada, Yukinori} } @article {114, title = {Genetics of 35 blood and urine biomarkers in the UK Biobank.}, journal = {Nat Genet}, volume = {53}, year = {2021}, month = {2021 02}, pages = {185-194}, abstract = {

Clinical laboratory tests are a critical component of the continuum of care. We evaluate the genetic basis of 35 blood and urine laboratory measurements in the UK Biobank (n = 363,228 individuals). We identify 1,857 loci associated with at least one trait, containing 3,374 fine-mapped associations and additional sets of large-effect (>0.1 s.d.) protein-altering, human leukocyte antigen (HLA) and copy number variant (CNV) associations. Through Mendelian randomization (MR) analysis, we discover 51 causal relationships, including previously known agonistic effects of urate on gout and cystatin C on stroke. Finally, we develop polygenic risk scores (PRSs) for each biomarker and build {\textquoteright}multi-PRS{\textquoteright} models for diseases using 35 PRSs simultaneously, which improved chronic kidney disease, type 2 diabetes, gout and alcoholic cirrhosis genetic risk stratification in an independent dataset (FinnGen; n = 135,500) relative to single-disease PRSs. Together, our results delineate the genetic basis of biomarkers and their causal influences on diseases and improve genetic risk stratification for common diseases.

}, keywords = {Biological Specimen Banks, Biomarkers, Cardiovascular Diseases, Diabetes Mellitus, Type 2, DNA Copy Number Variations, Genetic Pleiotropy, HLA Antigens, Humans, Linkage Disequilibrium, Liver-Specific Organic Anion Transporter 1, Mendelian Randomization Analysis, Polymorphism, Single Nucleotide, Proteins, Renal Insufficiency, Chronic, Serine Endopeptidases, United Kingdom}, issn = {1546-1718}, doi = {10.1038/s41588-020-00757-z}, author = {Sinnott-Armstrong, Nasa and Tanigawa, Yosuke and Amar, David and Mars, Nina and Benner, Christian and Aguirre, Matthew and Venkataraman, Guhan Ram and Wainberg, Michael and Ollila, Hanna M and Kiiskinen, Tuomo and Havulinna, Aki S and Pirruccello, James P and Qian, Junyang and Shcherbina, Anna and Rodriguez, Fatima and Assimes, Themistocles L and Agarwala, Vineeta and Tibshirani, Robert and Hastie, Trevor and Ripatti, Samuli and Pritchard, Jonathan K and Daly, Mark J and Rivas, Manuel A} } @article {121, title = {A fast and scalable framework for large-scale and ultrahigh-dimensional sparse regression with application to the UK Biobank.}, journal = {PLoS Genet}, volume = {16}, year = {2020}, month = {2020 10}, pages = {e1009141}, abstract = {

The UK Biobank is a very large, prospective population-based cohort study across the United Kingdom. It provides unprecedented opportunities for researchers to investigate the relationship between genotypic information and phenotypes of interest. Multiple regression methods, compared with genome-wide association studies (GWAS), have already been showed to greatly improve the prediction performance for a variety of phenotypes. In the high-dimensional settings, the lasso, since its first proposal in statistics, has been proved to be an effective method for simultaneous variable selection and estimation. However, the large-scale and ultrahigh dimension seen in the UK Biobank pose new challenges for applying the lasso method, as many existing algorithms and their implementations are not scalable to large applications. In this paper, we propose a computational framework called batch screening iterative lasso (BASIL) that can take advantage of any existing lasso solver and easily build a scalable solution for very large data, including those that are larger than the memory size. We introduce snpnet, an R package that implements the proposed algorithm on top of glmnet and optimizes for single nucleotide polymorphism (SNP) datasets. It currently supports l1-penalized linear model, logistic regression, Cox model, and also extends to the elastic net with l1/l2 penalty. We demonstrate results on the UK Biobank dataset, where we achieve competitive predictive performance for all four phenotypes considered (height, body mass index, asthma, high cholesterol) using only a small fraction of the variants compared with other established polygenic risk score methods.

}, keywords = {Algorithms, Asthma, Biological Specimen Banks, Body Height, Body Mass Index, Cholesterol, Cohort Studies, Genetics, Population, Genome-Wide Association Study, Genotype, Humans, Logistic Models, Phenotype, Polymorphism, Single Nucleotide, Proportional Hazards Models, United Kingdom}, issn = {1553-7404}, doi = {10.1371/journal.pgen.1009141}, author = {Qian, Junyang and Tanigawa, Yosuke and Du, Wenfei and Aguirre, Matthew and Chang, Chris and Tibshirani, Robert and Rivas, Manuel A and Hastie, Trevor} } @article {90, title = {Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma.}, journal = {PLoS Genet}, volume = {16}, year = {2020}, month = {2020 05}, pages = {e1008682}, abstract = {

Protein-altering variants that are protective against human disease provide in vivo validation of therapeutic targets. Here we use genotyping data from UK Biobank (n = 337,151 unrelated White British individuals) and FinnGen (n = 176,899) to conduct a search for protein-altering variants conferring lower intraocular pressure (IOP) and protection against glaucoma. Through rare protein-altering variant association analysis, we find a missense variant in ANGPTL7 in UK Biobank (rs28991009, p.Gln175His, MAF = 0.8\%, genotyped in 82,253 individuals with measured IOP and an independent set of 4,238 glaucoma patients and 250,660 controls) that significantly lowers IOP (β = -0.53 and -0.67 mmHg for heterozygotes, -3.40 and -2.37 mmHg for homozygotes, P = 5.96 x 10-9 and 1.07 x 10-13 for corneal compensated and Goldman-correlated IOP, respectively) and is associated with 34\% reduced risk of glaucoma (P = 0.0062). In FinnGen, we identify an ANGPTL7 missense variant at a greater than 50-fold increased frequency in Finland compared with other populations (rs147660927, p.Arg220Cys, MAF Finland = 4.3\%), which was genotyped in 6,537 glaucoma patients and 170,362 controls and is associated with a 29\% lower glaucoma risk (P = 1.9 x 10-12 for all glaucoma types and also protection against its subtypes including exfoliation, primary open-angle, and primary angle-closure). We further find three rarer variants in UK Biobank, including a protein-truncating variant, which confer a strong composite lowering of IOP (P = 0.0012 and 0.24 for Goldman-correlated and corneal compensated IOP, respectively), suggesting the protective mechanism likely resides in the loss of interaction or function. Our results support inhibition or down-regulation of ANGPTL7 as a therapeutic strategy for glaucoma.

}, keywords = {Adult, Aged, Aged, 80 and over, Angiopoietin-like Proteins, Biological Specimen Banks, Case-Control Studies, Cohort Studies, Female, Finland, Gene Frequency, Genetic Predisposition to Disease, Genetics, Population, Genome-Wide Association Study, Glaucoma, Humans, Intraocular Pressure, Loss of Function Mutation, Male, Middle Aged, Mutation, Missense, Polymorphism, Single Nucleotide, United Kingdom}, issn = {1553-7404}, doi = {10.1371/journal.pgen.1008682}, author = {Tanigawa, Yosuke and Wainberg, Michael and Karjalainen, Juha and Kiiskinen, Tuomo and Venkataraman, Guhan and Lemmel{\"a}, Susanna and Turunen, Joni A and Graham, Robert R and Havulinna, Aki S and Perola, Markus and Palotie, Aarno and Daly, Mark J and Rivas, Manuel A} } @article {41, title = {Global Biobank Engine: enabling genotype-phenotype browsing for biobank summary statistics.}, journal = {Bioinformatics}, volume = {35}, year = {2019}, month = {2019 Jul 15}, pages = {2495-2497}, abstract = {

SUMMARY: Large biobanks linking phenotype to genotype have led to an explosion of genetic association studies across a wide range of phenotypes. Sharing the knowledge generated by these resources with the scientific community remains a challenge due to patient privacy and the vast amount of data. Here, we present Global Biobank Engine (GBE), a web-based tool that enables exploration of the relationship between genotype and phenotype in biobank cohorts, such as the UK Biobank. GBE supports browsing for results from genome-wide association studies, phenome-wide association studies, gene-based tests and genetic correlation between phenotypes. We envision GBE as a platform that facilitates the dissemination of summary statistics from biobanks to the scientific and clinical communities.

AVAILABILITY AND IMPLEMENTATION: GBE currently hosts data from the UK Biobank and can be found freely available at biobankengine.stanford.edu.

}, keywords = {Biological Specimen Banks, Genome-Wide Association Study, Genotype, Humans, Phenomics, Phenotype}, issn = {1367-4811}, doi = {10.1093/bioinformatics/bty999}, author = {McInnes, Gregory and Tanigawa, Yosuke and DeBoever, Chris and Lavertu, Adam and Olivieri, Julia Eve and Aguirre, Matthew and Rivas, Manuel A} }